Site
Search results (Showing 1 - 10 of 122 results)
-
References | 1 Jun 2014
Interferon beta-1a for multiple sclerosis: old drug, new clothes.
-
References | 20 Sep 2005
10 years of interferon beta-1b (Beta feron therapy.
Kappos L, Hartung H-PJ Neurol. 2005 Sep; 252 Suppl 3:iii1-iii2. PMID: 16170493. Abstract -
References | 29 Jan 2013
Targeting two-pore domain potassium channels- A promising strategy for treating T cell mediated autoimmunity.
Kieseier BC, Hartung H-PExp Neurol. 2013 Jan 23. PMID: 23353639. Abstract -
References | 12 Dec 2013
Novel therapeutic options for multiple sclerosis.
Curtin F, Hartung H-PExpert Rev Clin Pharmacol. 2013 Dec 10. PMID: 24325127. Abstract -
References | 23 Apr 2014
The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives.
Hartung H-P, Kieseier BCCurr Opin Neurol. 2014 Jun; 27(3):243-5. PMID: 24751962. Abstract -
References | 9 Apr 2016
Steering through complexity: management approaches in multiple sclerosis.
Cree BAC, Hartung H-PCurr Opin Neurol. 2016 Apr 7. PMID: 27058222. Abstract -
References | 27 Mar 2007
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Neuhaus O, Kieseier BC, Hartung H-PJ Neurol Sci. 2007 Aug 15; 259(1-2):27-37. Epub 2007 Mar 27. PMID: 17391705. Abstract -
References | 21 Jun 2013
Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.
Warnke C, Kieseier BC, Hartung H-PJ Neural Transm. 2013 Jun 21. Epub 2013 Jun 21. PMID: 23793997. Abstract -
References | 25 Jun 2013
Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders.
Buttmann M, Kaveri S, Hartung H-PTrends Pharmacol Sci. 2013 Jun 20. PMID: 23791035. Abstract -
References | 24 Jun 2004
Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases.
Kieseier BC, Archelos JJ, Hartung H-PArch Neurol. 2004 Jun; 61(6):929-32. PMID: 15210533. Abstract